New drug candidates hold promise for European HIV drugs market, says F&S

The anticipated launch of drugs currently in the pipeline, together with the introduction of oral combination pills, are set to have a profound impact on the European HIV drugs market. A new analysis from Frost & Sullivan, Analysis of the European HIV Drugs Market, finds that the market earned $5.58 billion in 2012 and estimates this will reach $9.24 billion in 2019.

The research covers the most actively used antiretroviral (ARV) therapies: nucleoside reverse transcriptase inhibitor (NRTI), protease inhibitor (PI), non-nucleoside reverse transcriptase inhibitor (NNRTI), integrase inhibitors and other therapeutics (ARV compounds like CCR5 receptor antagonists, fusion inhibitors, maturation inhibitors, attachment inhibitors and PK boosters).

“In addition to popularly existing therapies like NRTI, NNRTI, PI and integrase inhibitors, new drug candidates over the last decade have spurred the HIV drugs market,” notes Frost & Sullivan health care research Analyst Deepika Pramod Chopda, adding: “The development of new candidates, derived from the less commonly used types of ARV therapies like PK boosters, maturation inhibitors, and attachment inhibitors, is driving the overall market.”